Search
A recent study from MSK investigators found that most patients who received genetic counseling by telemedicine during the early months of the pandemic reported being highly satisfied with the care they received.
A multidisciplinary team of Memorial Sloan Kettering investigators has shown for the first time that the gene that causes the inherited form of Parkinson's disease also plays a role in many types of cancer, including colon and lung cancers and glioblastoma, the most common form of brain cancer.
New drugs are being developed that target part of the process to make proteins.
Prostate cancer patients who are prescribed oral erectile medication before and after radiation therapy have improved sexual function, according to a research team at Memorial Sloan Kettering Cancer Center.
The pictures provide new clues about how the androgen receptor interacts with cancer-causing proteins.
Read about the latest findings in immunotherapy from the 2021 annual meeting of the American Society of Clinical Oncology (ASCO).
The lack of participation in clinical research may be the Achilles’ heel of today’s cancer community. According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted on behalf of Memorial Sloan Kettering Cancer Center (MSK), only 35 percent of Americans indicated that they were “likely” to enroll in a clinical trial. Other studies have shown that only 4 percent of cancer patients enroll in clinical trials nationally each year.
The Lehigh Valley Health Network (LVHN) Cancer Institute is now a formal member of the Memorial Sloan Kettering (MSK) Cancer Alliance, a transformative initiative to improve the quality of care and outcomes for people with cancer in community healthcare settings. Representatives of both organizations made the announcement today at Lehigh Valley Hospital–Cedar Crest following an intensive six-month collaborative review process.
Learn about a heartburn-related condition called Barrett’s esophagus and its connection to a higher risk of esophageal cancer.
Prognostic genetic testing is recommended for all patients with chronic lymphocytic leukemia (CLL). However, recent research shows that testing is infrequently performed and outcomes poorer in patients with unfavorable disease risk.